Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

35.34
BATS BZX Real-Time Price
As of 1:18pm ET
 -0.48 / -1.34%
Today’s Change
31.90
Today|||52-Week Range
59.35
-2.51%
Year-to-Date
TEVA Regular Dividend: TEVA will begin trading ex-dividend on 02/28/17 with a $0.34 dividend payable to shareholders of record as of 03/02/17.
3 Cheap Healthcare Stocks You Can Buy Right Now
12:10pm / MotleyFool.com - Paid Partner Content
Why Momenta Pharmaceuticals, Inc. Shares Got Crushed Today
Feb 21 / MotleyFool.com - Paid Partner Content
3 Stocks the Market Is Wrong About
Feb 23 / MotleyFool.com - Paid Partner Content
3 Top Drug Stocks That Can Be Purchased on the Cheap This Winter
Feb 20 / MotleyFool.com - Paid Partner Content
Go With Allergan, Celgene and 'Big Mo'
Feb 22 / TheStreet.com - Paid Partner Content
Drug Stocks Q4 Earnings Lineup for Feb 21: IRWD, MNTA, EXAS
Feb 20 / Zacks.com - Paid Partner Content
Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More
Feb 22 / Zacks.com - Paid Partner Content
River Wealth Advisors LLC Buys Vanguard Short-Termorate Bond ETF, Vanguard Total Bond...
Feb 17 / GuruFocus News - Paid Partner Content
Why Momenta Pharmaceuticals, Inc. Shares Got Crushed Today
Feb 21 / MotleyFool.com - Paid Partner Content
If You're in Your 30s, Consider Buying These Stocks
Feb 17 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close35.82
Today’s open35.78
Day’s range35.32 - 35.90
Volume208,748
Average volume (3 months)11,432,710
Market cap$36.3B
Dividend yield3.85%
Data as of 1:18pm ET, 02/24/2017

Growth & Valuation

Earnings growth (last year)-96.18%
Earnings growth (this year)-7.96%
Earnings growth (next 5 years)+1.00%
Revenue growth (last year)+12.01%
P/E ratio505.4
Price/Sales1.59
Price/Book--

Competitors

 Today’s
change
Today’s
% change
BGNEBeiGene Ltd+0.07+0.18%
OASMOasmia Pharmaceutica...-0.07-2.95%
Data as of 12:59pm ET, 02/24/2017

Financials

Next reporting dateMay 4, 2017
EPS forecast (this quarter)$1.09
Annual revenue (last year)$22.0B
Annual profit (last year)$330.0M
Net profit margin1.50%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
President &
Chief Executive Officer
Yitzhak Peterburg
President &
CEO-Global Operations
Carlo de Notaristefani
Corporate headquarters
Petach Tikva, Tel Aviv

Forecasts


Search for Jobs